TLX — Telix Pharmaceuticals Cashflow Statement
0.000.00%
HealthcareAdventurousMid CapMomentum Trap
- AU$1.17bn
- AU$1.15bn
- AU$7.60m
Annual cashflow statement for Telix Pharmaceuticals, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | |||||
Capital Expenditures | |||||
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | |||||
Acquisition of Business | |||||
Sale of Business | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | |||||
Financing Cash Flow Items | |||||
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | |||||
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash |